Funding for stereochemically pure Inclisiran (LEQVIO) siRNA diastereomers: synthesis and activity assessment (preclinical only)
This U01 supports research to synthesize each diastereomer of the GalNAc-conjugated siRNA drug Inclisiran (LEQVIO) and evaluate their biological activity. Projects will develop analytical methods and test PCSK9 inhibition in vitro and in animal models; clinical trials are not allowed. Results will inform sameness evaluations for generics and improve quality control for siRNA/oligonucleotide dr…
The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo …
Funding Source
Awards & funding
Eligibility
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH…
Supporting links
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers